COVID 19

Information about COVID 19

Monovalent MRNA COVID-19 Vaccines Update September 2023

The FDA granted approvals and emergency use authorizations to updated Moderna and Pfizer Covid- 19 vaccines. These updated 2023-24 formulations are monovalent (including one viral strain), designed to target the XBB.1.5 Omicron strain and to protect against serious consequences of this and other cross-reactive circulating SARS-CoV-2 variants.

https://www.fda.gov/news-events/press-announcements/fda-takes-action-updated-mrna-covid-19-vaccines-better-protect-against-currently-circulating

 

COVID-19 VACCINE INFORMATION

Bivalent (two viral strain) Moderna and Pfizer-BioNTech COVID-19 vaccines are no longer authorized in the U.S.

Monovalent COVID-19 vaccines for individuals 12 years of age and older are now FDA-approved and marketed as commercial products.

Pfizer-BioNTech – COMIRNATY® : Package Insert:
https://webfiles.pfizer.com/covid19dosing12yr

Moderna – SPIKEVAX® – Package Insert:
https://assets.modernatx.com/m/4fe30ac736607490/original/PPI-0017_Spikevax-2023-2024-Formula-Patient-Information-12y-US-English.pdf

Individuals 5 years of age and older regardless of previous vaccination are eligible to receive a single dose of an updated mRNA COVID-19 vaccine at least 2 months since the last dose of any COVID-19 vaccine. Please refer to the CDC’s Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States for additional clinical information and recommendations:
https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html

Per a CDC Health Alert Network memo, providers may simultaneously administer COVID-19, influenza, and respiratory syncytial virus (RSV) vaccines to eligible patients. Different anatomic sites should be used for vaccine administration (e.g., injections in same limb separated by at least 1 inch; high-dose influenza vaccines given in different limb).
https://emergency.cdc.gov/han/2023/han00498.asp